Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

Autor: Rugo, H.S. O'Shaughnessy, J. Boyle, F. Toi, M. Broom, R. Blancas, I. Gumus, M. Yamashita, T. Im, Y.-H. Rastogi, P. Zagouri, F. Song, C. Campone, M. San Antonio, B. Shahir, A. Hulstijn, M. Brown, J. Zimmermann, A. Wei, R. Johnston, S.R.D. Reinisch, M. Tolaney, S.M. monarchE Committee Members

BACKGROUND: In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::289b7b1ac47ba703c525e0b15a221484
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3219290

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

Autor: Johnston SRD; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: stephen.johnston@rmh.nhs.uk., Toi M; Kyoto University, Kyoto, Japan., O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA., Rastogi P; University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, PA, USA., Campone M; Institute de Cancérologie de l'Ouest, Centre Rene Cauducheau, Saint-Herblain, Nantes, France., Neven P; Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven, Belgium., Huang CS; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Huober J; Cantonal Hospital St Gallen, Breast Centre St Gallen, Switzerland., Jaliffe GG; Grupo Medico Camino SC, Mexico City, Mexico., Cicin I; Trakya University Faculty of Medicine, Edirne, Turkey., Tolaney SM; Dana-Farber Cancer Institute, Boston, MA, USA., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Rugo HS; University of California San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Senkus E; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland., Testa L; Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, Brazil., Del Mastro L; IRCSS Ospedale Policlinico San Martino, UO Breast Unit, Genoa, Italy; Università di Genova, Department of Internal Medicine and Medical Specialties (DIM), Genoa, Italy., Shimizu C; National Centre for Global Health and Medicine, Tokyo, Japan., Wei R; Eli Lilly and Company, Indianapolis, IN, USA., Shahir A; Loxo@Lilly, Indianapolis, IN, USA., Munoz M; Loxo@Lilly, Indianapolis, IN, USA., San Antonio B; Loxo@Lilly, Indianapolis, IN, USA., André V; Eli Lilly and Company, Indianapolis, IN, USA., Harbeck N; Breast Centre, Department of Gynaecology and Obstetrics, Comprehensive Cancer Centre München, LMU University Hospital, Munich, Germany., Martin M; Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2023 Jan; Vol. 24 (1), pp. 77-90. Date of Electronic Publication: 2022 Dec 06.

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.

Autor: Harbeck N; Breast Center, Department of OB & GYN and CCC Munich, LMU University Hospital, Munich, Germany. Electronic address: Nadia.Harbeck@med.uni-muenchen.de., Rastogi P; University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA., Martin M; Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain., Tolaney SM; Dana-Farber Cancer Institute, Boston, USA., Shao ZM; Fudan University Shanghai Cancer Center, Shanghai, China., Fasching PA; University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany., Huang CS; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Jaliffe GG; Grupo Medico Camino S.C., Mexico City, Mexico., Tryakin A; N.N.Blokhin Russian Cancer Research Center, Moscow, Russia., Goetz MP; Mayo Clinic, Rochester, USA., Rugo HS; Department of Medicine (Hematology/Oncology), University of California San Francisco, San Francisco, USA., Senkus E; Department of Oncology & Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland., Testa L; Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, Brazil., Andersson M; Rigshospitalet, Copenhagen, Denmark., Tamura K; National Cancer Center Hospital, Tokyo, Japan., Del Mastro L; IRCSS Ospedale Policlinico San Martino, UO Breast Unit, Genoa, Italy; Università di Genova, Department of Internal Medicine and Medical Specialties (DIM), Genoa, Italy., Steger GG; Medical University of Vienna, Vienna, Austria., Kreipe H; Medizinische Hochschule Hannover, Hannover, Germany., Hegg R; Clin. Pesq. e Centro São Paulo, São Paulo, Brazil., Sohn J; Yonsei Cancer Center, Seoul, Korea., Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy; Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy., Cortés J; International Breast Cancer Center (IBCC), Madrid & Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain., Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA., André V; Eli Lilly and Company, Indianapolis, USA., Wei R; Eli Lilly and Company, Indianapolis, USA., Barriga S; Eli Lilly and Company, Indianapolis, USA., Sherwood S; Eli Lilly and Company, Indianapolis, USA., Forrester T; Eli Lilly and Company, Indianapolis, USA., Munoz M; Eli Lilly and Company, Indianapolis, USA., Shahir A; Eli Lilly and Company, Indianapolis, USA., San Antonio B; Eli Lilly and Company, Indianapolis, USA., Nabinger SC; Eli Lilly and Company, Indianapolis, USA., Toi M; Kyoto University Hospital, Kyoto, Japan., Johnston SRD; Royal Marsden NHS Foundation Trust, London, UK., O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Dec; Vol. 32 (12), pp. 1571-1581. Date of Electronic Publication: 2021 Oct 14.

An original study assessing biomarker success rate in breast cancer recurrence biomarker research.

Autor: Savva, K-V.¹ (AUTHOR) k.savva17@imperial.ac.uk, MacKenzie, A.² (AUTHOR), Coombes, R. C.¹ (AUTHOR), Zhifang, N. M.² (AUTHOR), Hanna, B. G.¹ (AUTHOR), Peters, C. J.¹ (AUTHOR)

Publikováno v: BMC Medicine. 7/29/2024, Vol. 22 Issue 1, p1-12. 12p.

Identification of MicroRNAs Associated with Histological Grade in Early-Stage Invasive Breast Cancer.

Autor: Kurozumi, Sasagu^1,2 (AUTHOR) ftakaaki@gunma-u.ac.jp, Seki, Naohiko³ (AUTHOR) naoseki@faculty.chiba-u.jp, Narusawa, Eriko² (AUTHOR), Honda, Chikako² (AUTHOR), Tokuda, Shoko² (AUTHOR), Nakazawa, Yuko² (AUTHOR), Yokobori, Takehiko⁴ (AUTHOR), Katayama, Ayaka⁵ (AUTHOR) oyama@gunma-u.ac.jp, Mongan, Nigel P.⁶ (AUTHOR), Rakha, Emad A.^7,8 (AUTHOR), Oyama, Tetsunari⁵ (AUTHOR), Fujii, Takaaki² (AUTHOR), Shirabe, Ken² (AUTHOR), Horiguchi, Jun¹ (AUTHOR)

Publikováno v: International Journal of Molecular Sciences. Jan2024, Vol. 25 Issue 1, p35. 11p.